The proof-of-concept of ASS234: Peripherally administered ASS234 enters the central nervous system and reduces pathology in a male mouse model of Alzheimer disease

BACKGROUND: The heterogeneity of Alzheimer disease requires the development of multitarget drugs for treating the symptoms of the disease and its progression. Both cholinergic and monoamine oxidase dysfunctions are involved in the pathological process. Thus, we hypothesized that the development of t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Psychiatry Neurosci
Main Authors: Serrano, Mari Paz, Herrero-Labrador, Raquel, Futch, Hunter S., Serrano, Julia, Romero, Alejandro, Fernandez, Ana Patricia, Samadi, Abdelouahid, Unzeta, Mercedes, Marco-Contelles, Jose, Martínez-Murillo, Ricardo
Formato: Artigo
Idioma:Inglês
Publicado em: Joule Inc. 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5373713/
https://ncbi.nlm.nih.gov/pubmed/27636528
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1503/jpn.150209
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados